Shares of Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) were up 7.3% on Tuesday . The company traded as high as $5.23 and last traded at $5.19. Approximately 7,337,377 shares were traded during mid-day trading, a decline of 52% from the average daily volume of 15,417,245 shares. The stock had previously closed at $4.83.
Wall Street Analyst Weigh In
A number of equities research analysts have weighed in on RXRX shares. Morgan Stanley reduced their target price on Recursion Pharmaceuticals from $8.00 to $5.00 and set an "equal weight" rating on the stock in a report on Monday, June 16th. Needham & Company LLC dropped their price target on Recursion Pharmaceuticals from $11.00 to $8.00 and set a "buy" rating for the company in a research note on Tuesday, May 6th. Leerink Partners dropped their price target on Recursion Pharmaceuticals from $7.00 to $6.00 and set a "market perform" rating for the company in a research note on Friday, February 28th. Finally, Cowen reiterated a "hold" rating on shares of Recursion Pharmaceuticals in a research note on Friday, February 28th. Four investment analysts have rated the stock with a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of "Hold" and a consensus price target of $7.00.
Get Our Latest Stock Analysis on RXRX
Recursion Pharmaceuticals Stock Performance
The company has a 50-day moving average price of $4.91 and a two-hundred day moving average price of $6.23. The company has a current ratio of 4.11, a quick ratio of 4.11 and a debt-to-equity ratio of 0.02. The stock has a market capitalization of $2.13 billion, a P/E ratio of -2.97 and a beta of 0.84.
Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last posted its quarterly earnings data on Monday, May 5th. The company reported ($0.50) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.06). Recursion Pharmaceuticals had a negative return on equity of 74.70% and a negative net margin of 961.32%. The business had revenue of $14.75 million during the quarter, compared to the consensus estimate of $18.12 million. During the same period last year, the business posted ($0.39) earnings per share. The business's revenue was up 7.2% on a year-over-year basis. On average, equities analysts forecast that Recursion Pharmaceuticals, Inc. will post -1.57 earnings per share for the current year.
Institutional Trading of Recursion Pharmaceuticals
Large investors have recently made changes to their positions in the company. Private Trust Co. NA acquired a new stake in shares of Recursion Pharmaceuticals in the 4th quarter valued at about $27,000. AlphaQuest LLC acquired a new stake in shares of Recursion Pharmaceuticals in the 1st quarter valued at about $36,000. GAMMA Investing LLC grew its stake in shares of Recursion Pharmaceuticals by 39.0% in the 1st quarter. GAMMA Investing LLC now owns 7,224 shares of the company's stock valued at $38,000 after buying an additional 2,026 shares during the period. Farther Finance Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 21.1% in the 4th quarter. Farther Finance Advisors LLC now owns 7,757 shares of the company's stock valued at $52,000 after buying an additional 1,353 shares during the period. Finally, NewEdge Advisors LLC grew its stake in shares of Recursion Pharmaceuticals by 43.7% in the 4th quarter. NewEdge Advisors LLC now owns 7,847 shares of the company's stock valued at $53,000 after buying an additional 2,387 shares during the period. 89.06% of the stock is currently owned by institutional investors and hedge funds.
About Recursion Pharmaceuticals
(
Get Free Report)
Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Recursion Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Recursion Pharmaceuticals wasn't on the list.
While Recursion Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Summer 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
